SynthesisJournal of gastrointestinal cancer2026
Prognostic Value of Pretreatment C-Reactive-Protein-Albumin-Lymphocyte Index in Colorectal Cancer: Systematic Review and Meta-Analysis.
Synthesis in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-term postdischarge immunonutrition management in elective colorectal cancer surgery patients an interim analysis of a Chinese multicenter randomised controlled trial.Metabolism open · 2026Article
- Comment on "Prognostic Value of Pretreatment C-Reactive-Protein-Albumin-Lymphocyte Index in Colorectal Cancer: Systematic Review and Meta-Analysis".Journal of gastrointestinal cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the prognostic value of the C-reactive–protein–Albumin–Lymphocyte (CALLY) index has been reported across several cancers, its role in colorectal cancer (CRC) remains uncertain. We conducted a systematic review and meta-analysis to evaluate the prognostic utility of the pretreatment CALLY index in CRC patients.
methodsFollowing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched PubMed, Web of Science, Scopus, Embase, and Google Scholar from inception to 15 February 2026 for studies including adults with histologically confirmed CRC that reported pretreatment CALLY and time-to-event outcomes (overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), and/or progression-free survival (PFS)). Hazard ratios (HRs) were pooled using random-effects models. Heterogeneity was assessed with I² and τ²; small-study effects were explored with Egger’s test.
resultsFifteen studies (16 independent groups; n = 9179) met the inclusion criteria. A higher CALLY index was associated with improved OS (pooled HR 0.556, 95% confidence intervals (CIs) 0.464–0.666; I² = 72.0%; 12 cohorts) and pooled DFS/RFS (HR 0.712, 95% CI 0.634-0.800; I² = 14.6%; 9 cohorts), with limited evidence for PFS (HR 0.324, 95% CI 0.178–0.589; I² = 76.0%; 3 cohorts).
conclusionsA higher pretreatment CALLY is associated with longer OS and DFS/RFS in patients with CRC. Limited evidence also suggests an association with improved PFS. These findings suggest that pretreatment CALLY may be useful for risk stratification, but prospective validation and standardized cutoffs are needed before routine clinical adoption.
Indexed as
Identifiers
41860688What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.